Lipoic acid (LA) is an antioxidant that is effective in treating experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS). C57BL/6 mice with EAE develop experimental autoimmune optic neuritis (EAON), which models acute optic neuritis in humans. Here we determined whether LA is therapeutically effective in EAON. We immunized C57BL/6 mice with MOG 35-55 peptide. Mice received either daily subcutaneous injections of LA (100 mg/kg) or saline in early or late suppression paradigms. In the early suppression paradigm, optic nerve cross-sections showed 14.9 ± 3.8% (mean ± SEM) damage in mice receiving saline (n = 7) and 2.0 ± 0.4% damage in mice given LA (n = 7, p = 0.001). In the late suppression paradigm, optic nerve sections showed 24.6 ± 3.5% damage in mice treated with saline (n = 7) and 8.4 ± 2.5% in mice treated with LA (n = 7, p = 0.004). Thus a dramatic reduction in axonal injury was seen after LA administration in both experimental paradigms. Compared with saline treated mice with EAON, optic nerves from mice receiving LA had significantly fewer CD4+ and CD11b+ cells in both paradigms. This study provides a rationale for investigating the therapeutic efficacy of LA in acute optic neuritis in humans.
Introduction
Acute optic neuritis (AON) can occur in isolation or as a manifestation of multiple sclerosis (MS) and results in demyelination and variable axonal loss in the optic nerve. While high dose methylprednisolone can speed up recovery from AON, there are presently no treatments to prevent axonal damage in AON (Abou Zeid and Bhatti, 2008; Shams and Plant, 2009) . Experimental autoimmune encephalomyelitis (EAE) in mice is used as a model system for MS. Experimental autoimmune optic neuritis (EAON) frequently occurs in mice with EAE and models AON (Shao et al., 2004; Shindler et al., 2006) . EAON models have been used as a standard system to study the pathogenesis and treatment of AON (Maier et al., 2006; Qi et al., 2007; Sattler et al., 2004) .
Degeneration of axons causes impairment of vision following AON and permanent disability in MS. The mechanisms of axon loss in both are being investigated. Changes in ion channels, cytoskeletal pathology, reduced ATP production, and decreased axonal transport all may contribute to axonal degeneration (Dutta et al., 2006; Young et al., 2008) . Mitochondrial dysfunction and oxidative stress have come into focus recently and are believed to play a major role in the degeneration of axons in inflammatory disorders of the CNS, such as AON and MS (Dutta et al., 2006; Forte et al., 2007; Guy, 2008; Kalman and Leist, 2003; Smith and Lassmann, 2002) .
Lipoic acid (LA) is a natural antioxidant that suppresses and treats EAE (Chaudhary et al., 2006; Marracci et al., 2002; Morini et al., 2004; Schreibelt et al., 2006) . LA mediates its effect by inhibiting T cell migration into the CNS, decreasing endothelial cell adhesion molecule expression and causing a reduction in MMP-9 production. Recently, we found that LA stimulates cAMP production via G protein coupled prostaglandin EP2 and EP4 receptors on immune cells (Salinthone et al., 2008; Schillace et al., 2007) . cAMP is an important secondary messenger involved in signal transduction pathways (Kamenetsky et al., 2006) and cAMP regulatory pathways play a role in immunoregulation and neuroprotection. Thus, cAMP might be vital to the therapeutic effects of LA (Silveira and Linden, 2006) . Protection against loss of axons is central to development of therapies for AON and MS. In this study we assess the effects of LA in EAON for the first time and demonstrate that LA significantly reduces axonal injury in EAON.
Materials and Methods

EAON induction and assessment
C57BL/6 (The Jackson Laboratory, Bar Harbor, ME) female mice were immunized with 200 μg of MOG 35-55 peptide in complete Freund's adjuvant containing 400 μg of Mycobacterium tuberculosis per mouse by Journal of Neuroimmunology 233 (2011) 90-96 
